T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma

Trial Profile

T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Interleukin-2 (Primary) ; Tumour infiltrating lymphocytes (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 16 Mar 2018 Planned End Date changed from 1 Nov 2017 to 1 Aug 2020.
    • 16 Mar 2018 Planned primary completion date changed from 1 Nov 2016 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top